Trials / Conditions / Moderate or Severe Submental Fullness

Moderate or Severe Submental Fullness

12 registered clinical trials studyying Moderate or Severe Submental Fullness — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation NCT06756490	Sichuan Huiyu Pharmaceutical Co., Ltd	Phase 1
Completed	Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area NCT05266729	AMIpharm Co., Ltd.	Phase 2
Completed	Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Subme NCT03982225	AMIpharm Co., Ltd.	Phase 2
Completed	Patient Experience Study of Deoxycholic Acid Injection NCT02007434	Kythera Biopharmaceuticals	Phase 3
Completed	Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneo NCT01546142	Kythera Biopharmaceuticals	Phase 3
Completed	Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneo NCT01542034	Kythera Biopharmaceuticals	Phase 3
Completed	Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area NCT01426373	Kythera Biopharmaceuticals	Phase 3
Completed	Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat NCT01294644	Kythera Biopharmaceuticals	Phase 3
Completed	Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat NCT01305577	Kythera Biopharmaceuticals	Phase 3
Completed	Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome M NCT01032889	Kythera Biopharmaceuticals	Phase 2
Completed	Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat NCT00618618	Kythera Biopharmaceuticals	Phase 2
Completed	Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat NCT00618722	Kythera Biopharmaceuticals	Phase 1 / Phase 2